On the stock market since 2025, it operates in the world of health and science. It has 40 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit indicators sit around the sector average.
Clearly below the class average.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 93% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $2.9M in the vault; even if every debt were paid off, $1.6M would remain.
A loss of $102K against $0 in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 34/100.
As the slice kept from each sale thins out, so does the profit.
On our five-subject report card, ADVB sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: ADVB is a high-risk stock — not yet profitable, and its future rides on its product catching on.